Aging increases cytochrome P450 4A modulation of α1-adrenergic vasoconstriction in mesenteric arteries

Dellice J. Berezan, Kathryn M J Dunn, J R Falck, Sandra T. Davidge

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aging is associated with peripheral vascular dysfunction. In vascular smooth muscle, cytochrome P450 4A (CYP4A) enzymes form the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE acts as an intracellular messenger to modulate vasoconstriction induced by various agonists, including the α1-adrenergic agonist phenylephrine (PE) and endothelin-1 (ET-1). Eicosanoids produced by CYP4A contribute to the elevated vascular tone in hypertension, but the effects of advanced age on CYP4A modulation of vasoconstriction are unknown. Mesenteric arteries were isolated from young (3 to 4 months) and aged (17 to 18 months) Sprague-Dawley rats. Vasoconstriction was induced with PE or ET-1 in the absence or presence of the CYP4A inhibitor DDMS and/or the ETA inhibitor BQ123. CYP4A inhibition with DDMS significantly reduced PE sensitivity in aged rats, but it had no effect in young. Furthermore, in aged rats only, ETA inhibition reduced PE sensitivity while combined inhibition of CYP4A and ETA had no additional effect, suggesting that the pathways work in concert in aging. Exogenous ET-1 constriction was not altered by DDMS in young or aged rats. Overall, our data indicate that aging increases the contribution of CYP4A to α1-adrenergic vasoconstriction in systemic arteries. Understanding aging-related changes in vascular function is important for development of novel targets for the prevention of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)327-330
Number of pages4
JournalJournal of Cardiovascular Pharmacology
Volume51
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Mesenteric Arteries
Vasoconstriction
Adrenergic Agents
Cytochrome P-450 Enzyme System
Phenylephrine
Endothelin-1
Blood Vessels
Adrenergic Agonists
Eicosanoids
Vasoconstrictor Agents
Vascular Smooth Muscle
Constriction
Sprague Dawley Rats
Cardiovascular Diseases
Arteries
Hypertension

Keywords

  • 20-HETE
  • Aging
  • CYP4A
  • Mesenteric arteries
  • Rat
  • Vasoconstriction

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Aging increases cytochrome P450 4A modulation of α1-adrenergic vasoconstriction in mesenteric arteries. / Berezan, Dellice J.; Dunn, Kathryn M J; Falck, J R; Davidge, Sandra T.

In: Journal of Cardiovascular Pharmacology, Vol. 51, No. 3, 03.2008, p. 327-330.

Research output: Contribution to journalArticle

Berezan, Dellice J. ; Dunn, Kathryn M J ; Falck, J R ; Davidge, Sandra T. / Aging increases cytochrome P450 4A modulation of α1-adrenergic vasoconstriction in mesenteric arteries. In: Journal of Cardiovascular Pharmacology. 2008 ; Vol. 51, No. 3. pp. 327-330.
@article{a9b6eca01c884e60aa457d803c13a71f,
title = "Aging increases cytochrome P450 4A modulation of α1-adrenergic vasoconstriction in mesenteric arteries",
abstract = "Aging is associated with peripheral vascular dysfunction. In vascular smooth muscle, cytochrome P450 4A (CYP4A) enzymes form the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE acts as an intracellular messenger to modulate vasoconstriction induced by various agonists, including the α1-adrenergic agonist phenylephrine (PE) and endothelin-1 (ET-1). Eicosanoids produced by CYP4A contribute to the elevated vascular tone in hypertension, but the effects of advanced age on CYP4A modulation of vasoconstriction are unknown. Mesenteric arteries were isolated from young (3 to 4 months) and aged (17 to 18 months) Sprague-Dawley rats. Vasoconstriction was induced with PE or ET-1 in the absence or presence of the CYP4A inhibitor DDMS and/or the ETA inhibitor BQ123. CYP4A inhibition with DDMS significantly reduced PE sensitivity in aged rats, but it had no effect in young. Furthermore, in aged rats only, ETA inhibition reduced PE sensitivity while combined inhibition of CYP4A and ETA had no additional effect, suggesting that the pathways work in concert in aging. Exogenous ET-1 constriction was not altered by DDMS in young or aged rats. Overall, our data indicate that aging increases the contribution of CYP4A to α1-adrenergic vasoconstriction in systemic arteries. Understanding aging-related changes in vascular function is important for development of novel targets for the prevention of cardiovascular disease.",
keywords = "20-HETE, Aging, CYP4A, Mesenteric arteries, Rat, Vasoconstriction",
author = "Berezan, {Dellice J.} and Dunn, {Kathryn M J} and Falck, {J R} and Davidge, {Sandra T.}",
year = "2008",
month = "3",
doi = "10.1097/FJC.0b013e318160b415",
language = "English (US)",
volume = "51",
pages = "327--330",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Aging increases cytochrome P450 4A modulation of α1-adrenergic vasoconstriction in mesenteric arteries

AU - Berezan, Dellice J.

AU - Dunn, Kathryn M J

AU - Falck, J R

AU - Davidge, Sandra T.

PY - 2008/3

Y1 - 2008/3

N2 - Aging is associated with peripheral vascular dysfunction. In vascular smooth muscle, cytochrome P450 4A (CYP4A) enzymes form the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE acts as an intracellular messenger to modulate vasoconstriction induced by various agonists, including the α1-adrenergic agonist phenylephrine (PE) and endothelin-1 (ET-1). Eicosanoids produced by CYP4A contribute to the elevated vascular tone in hypertension, but the effects of advanced age on CYP4A modulation of vasoconstriction are unknown. Mesenteric arteries were isolated from young (3 to 4 months) and aged (17 to 18 months) Sprague-Dawley rats. Vasoconstriction was induced with PE or ET-1 in the absence or presence of the CYP4A inhibitor DDMS and/or the ETA inhibitor BQ123. CYP4A inhibition with DDMS significantly reduced PE sensitivity in aged rats, but it had no effect in young. Furthermore, in aged rats only, ETA inhibition reduced PE sensitivity while combined inhibition of CYP4A and ETA had no additional effect, suggesting that the pathways work in concert in aging. Exogenous ET-1 constriction was not altered by DDMS in young or aged rats. Overall, our data indicate that aging increases the contribution of CYP4A to α1-adrenergic vasoconstriction in systemic arteries. Understanding aging-related changes in vascular function is important for development of novel targets for the prevention of cardiovascular disease.

AB - Aging is associated with peripheral vascular dysfunction. In vascular smooth muscle, cytochrome P450 4A (CYP4A) enzymes form the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE acts as an intracellular messenger to modulate vasoconstriction induced by various agonists, including the α1-adrenergic agonist phenylephrine (PE) and endothelin-1 (ET-1). Eicosanoids produced by CYP4A contribute to the elevated vascular tone in hypertension, but the effects of advanced age on CYP4A modulation of vasoconstriction are unknown. Mesenteric arteries were isolated from young (3 to 4 months) and aged (17 to 18 months) Sprague-Dawley rats. Vasoconstriction was induced with PE or ET-1 in the absence or presence of the CYP4A inhibitor DDMS and/or the ETA inhibitor BQ123. CYP4A inhibition with DDMS significantly reduced PE sensitivity in aged rats, but it had no effect in young. Furthermore, in aged rats only, ETA inhibition reduced PE sensitivity while combined inhibition of CYP4A and ETA had no additional effect, suggesting that the pathways work in concert in aging. Exogenous ET-1 constriction was not altered by DDMS in young or aged rats. Overall, our data indicate that aging increases the contribution of CYP4A to α1-adrenergic vasoconstriction in systemic arteries. Understanding aging-related changes in vascular function is important for development of novel targets for the prevention of cardiovascular disease.

KW - 20-HETE

KW - Aging

KW - CYP4A

KW - Mesenteric arteries

KW - Rat

KW - Vasoconstriction

UR - http://www.scopus.com/inward/record.url?scp=41349084425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349084425&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e318160b415

DO - 10.1097/FJC.0b013e318160b415

M3 - Article

C2 - 18356699

AN - SCOPUS:41349084425

VL - 51

SP - 327

EP - 330

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -